OLFM4 and neoplasm: Notably, we also found that IL11+CD10+ iCAFs were a key component of CSC niche that drive tumor stemness in CSCs by upregulating the expression of SOX9 and OLFM4, leading to drug resistance via the AREG‐ERBB2 signaling pathway.